Archived explainer. For the current picture see today's SLS page.
Why Is SELLAS LIFE SCIENCES (SLS) Stock Up Today?
By the Top Tier Newswire AI Desk · August 12, 2026 at 9:48 AM ET · reviewed against 7 wire stories
SELLAS LIFE SCIENCES (SLS) is up +7.65% in the latest session. Our newswire has captured 7 stories on SLS across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
SELLAS Life Sciences stock is up 7.65% to $11.89 in early trading on August 12, 2026, driven by a combination of clinical progress updates and a robust cash position. The biotech firm reported a strong balance sheet with $138.3 million in cash and provided updates on key clinical programs, including the Phase 3 REGAL trial of Galinpepimut-S (GPS) in acute myeloid leukemia. These developments have fueled investor optimism ahead of major data readouts.
What Happened
The stock opened with a modest 0.5% gap up from the previous close of $11.05 and quickly surged to an intraday high of $12.45 shortly after 9:30 AM ET. The upward momentum followed the release of the company’s second-quarter financial results and a corporate update. SELLAS reported a net loss of $9.6 million, or $0.05 per share, for the quarter ended June 30, which matched the updated earnings expectation. The firm also announced that the final analysis of the Phase 3 REGAL trial is progressing and that 28 patients have been enrolled in the Phase 2 trial of SLS009. These updates, combined with the company’s growing R&D investment and strong cash reserves, have positioned SELLAS for key clinical milestones in AML and pancreatic cancer.
What The Data Shows
The stock has gained 10.3% over the past eight trading sessions, rising from $9.94 to $10.96. Today’s session volume of 1.3 million shares is roughly 20% of the 3-month daily average, indicating moderate but notable participation. The stock is currently trading within its 52-week range of $1.39 to $15.88, though it remains unprofitable with a trailing 12-month EPS of -0.23. Options activity also suggests a potential 8.0% move post-earnings, highlighting the market’s anticipation for the upcoming data readouts.
What To Watch
Investors should monitor the final analysis of the Phase 3 REGAL trial and the progress of the Phase 2 SLS009 trial for further catalysts. The stock’s performance could also be influenced by any additional clinical updates or financial developments in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SLS · today's session (5-min) · +6.42% vs prior close · updated 2:07 PM ETAI sentiment, last 36h · averaged over 7 stories · 54/100 neutral
The headlines behind the move
Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
4h agoMarketChameleonBULLISH 67Product/PR
Strong Cash Position Supports SELLAS as GPS and SLS009 Progress Toward Major Clinical Milestones
August 12, 2026
SELLAS Life Sciences reports robust Phase 3 and Phase 2 program advancements, growing R&D investment, and a cash balance of $138.3M, setting the stage for key data readouts and clinical expansion in AML and pancreatic cancer.
18h agoStocktwits NewsNEUTRAL 48Earnings
SLS Stock Holds Steady After Q2 Update — Investors Eye End Of GPS Quiet Period
The biotech, focused on novel cancer therapies, reported a net loss of $9.6 million, or $0.05 per share, for the quarter ended June 30.
22h agoSEC 8-KNEUTRAL 50General
SELLAS Life Sciences Group, Inc. (SLS) files 8-K
Filed: 2026-08-11 AccNo: 0001390478-26-000013 Size: 229 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
22h agoStockTitanNEUTRAL 50Earnings
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase...
1d agoThe FlyBULLISH 56Earnings
Sellas Life Sciences options imply 8.0% move in share price post-earnings
1d agoStocktwits NewsNEUTRAL 53Macro
S&P 500, Nasdaq, Dow Futures Mixed As CPI Countdown Begins: Why INTC, SLS, SPCX, RKLB, ASTS, RIOT, FRMI Stocks Are In Focus
Retail sentiment on Stocktwits has declined to ‘neutral’ on SPY and ‘extremely bearish’ on QQQ.
1d agoStocktwits NewsNEUTRAL 53Earnings
SLS Stock Rebounds Premarket After Worst Day In 3 Weeks — Retail Awaits ‘Very Special’ Earnings Update
Wall Street expects no quarterly revenue and a GAAP loss of $0.04 per share, narrowing from $0.05 previously.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →